418 related articles for article (PubMed ID: 25172198)
1. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study.
Chew EY; Davis MD; Danis RP; Lovato JF; Perdue LH; Greven C; Genuth S; Goff DC; Leiter LA; Ismail-Beigi F; Ambrosius WT;
Ophthalmology; 2014 Dec; 121(12):2443-51. PubMed ID: 25172198
[TBL] [Abstract][Full Text] [Related]
2. Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.
Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group
Diabetes Care; 2016 Jul; 39(7):1089-100. PubMed ID: 27289122
[TBL] [Abstract][Full Text] [Related]
3. Effects of medical therapies on retinopathy progression in type 2 diabetes.
; ; Chew EY; Ambrosius WT; Davis MD; Danis RP; Gangaputra S; Greven CM; Hubbard L; Esser BA; Lovato JF; Perdue LH; Goff DC; Cushman WC; Ginsberg HN; Elam MB; Genuth S; Gerstein HC; Schubart U; Fine LJ
N Engl J Med; 2010 Jul; 363(3):233-44. PubMed ID: 20587587
[TBL] [Abstract][Full Text] [Related]
4. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.
Keech AC; Mitchell P; Summanen PA; O'Day J; Davis TM; Moffitt MS; Taskinen MR; Simes RJ; Tse D; Williamson E; Merrifield A; Laatikainen LT; d'Emden MC; Crimet DC; O'Connell RL; Colman PG;
Lancet; 2007 Nov; 370(9600):1687-97. PubMed ID: 17988728
[TBL] [Abstract][Full Text] [Related]
5. Fenofibrate for diabetic retinopathy.
Kataoka SY; Lois N; Kawano S; Kataoka Y; Inoue K; Watanabe N
Cochrane Database Syst Rev; 2023 Jun; 6(6):CD013318. PubMed ID: 37310870
[TBL] [Abstract][Full Text] [Related]
6. Fenofibrate - a potential systemic treatment for diabetic retinopathy?
Wong TY; Simó R; Mitchell P
Am J Ophthalmol; 2012 Jul; 154(1):6-12. PubMed ID: 22709833
[TBL] [Abstract][Full Text] [Related]
7. Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies.
Wright AD; Dodson PM
Eye (Lond); 2011 Jul; 25(7):843-9. PubMed ID: 21436845
[TBL] [Abstract][Full Text] [Related]
8. Systemic therapies for diabetic retinopathy: the accord eye study.
Frank RN
Ophthalmology; 2014 Dec; 121(12):2295-6. PubMed ID: 25459462
[No Abstract] [Full Text] [Related]
9. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial.
Margolis KL; O'Connor PJ; Morgan TM; Buse JB; Cohen RM; Cushman WC; Cutler JA; Evans GW; Gerstein HC; Grimm RH; Lipkin EW; Narayan KM; Riddle MC; Sood A; Goff DC
Diabetes Care; 2014 Jun; 37(6):1721-8. PubMed ID: 24595629
[TBL] [Abstract][Full Text] [Related]
10. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
[TBL] [Abstract][Full Text] [Related]
11. Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE).
Chew EY; Ambrosius WT; Howard LT; Greven CM; Johnson S; Danis RP; Davis MD; Genuth S; Domanski M;
Am J Cardiol; 2007 Jun; 99(12A):103i-111i. PubMed ID: 17599420
[TBL] [Abstract][Full Text] [Related]
12. Prevention and treatment of diabetic retinopathy: evidence from large, randomized trials. The emerging role of fenofibrate.
Simó R; Hernández C
Rev Recent Clin Trials; 2012 Feb; 7(1):71-80. PubMed ID: 21864248
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes.
Mottl AK; Buse JB; Ismail-Beigi F; Sigal RJ; Pedley CF; Papademetriou V; Simmons DL; Katz L; Mychaleckyj JC; Craven TE
Clin J Am Soc Nephrol; 2018 Nov; 13(11):1693-1702. PubMed ID: 30361335
[TBL] [Abstract][Full Text] [Related]
14. Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
Keating GM
Am J Cardiovasc Drugs; 2011 Aug; 11(4):227-47. PubMed ID: 21675801
[TBL] [Abstract][Full Text] [Related]
15. Fenofibrate for Diabetic Retinopathy.
Stewart S; Lois N
Asia Pac J Ophthalmol (Phila); 2018; 7(6):422-426. PubMed ID: 30058790
[TBL] [Abstract][Full Text] [Related]
16. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
[TBL] [Abstract][Full Text] [Related]
17. Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives.
Simó R; Roy S; Behar-Cohen F; Keech A; Mitchell P; Wong TY
Curr Med Chem; 2013; 20(26):3258-66. PubMed ID: 23745548
[TBL] [Abstract][Full Text] [Related]
18. How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD.
Steiner G
Cardiovasc Drugs Ther; 2009 Oct; 23(5):403-8. PubMed ID: 19757004
[TBL] [Abstract][Full Text] [Related]
19. Blood pressure control for diabetic retinopathy.
Do DV; Wang X; Vedula SS; Marrone M; Sleilati G; Hawkins BS; Frank RN
Cochrane Database Syst Rev; 2015 Jan; 1():CD006127. PubMed ID: 25637717
[TBL] [Abstract][Full Text] [Related]
20. Lack of Longitudinal Association Between Thiazolidinediones and Incidence and Progression of Diabetic Eye Disease: The ACCORD Eye Study.
Gower EW; Lovato JF; Ambrosius WT; Chew EY; Danis RP; Davis MD; Goff DC; Greven CM;
Am J Ophthalmol; 2018 Mar; 187():138-147. PubMed ID: 29275147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
